DOCSLIB.ORG

Excitatory Synapse

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Excitatory Synapse Excitatory synapse Vti1a β Synptop SCAMP brevin hysin ptot Synaptic Syna mGluR Actin vesicle Synptogyrin Synaptotagmin Gi/o SV2 (2A,2B,2 Synapsin SVOSSV PRA1 C) α OPO PRA1 A/3B P WNT Fz R 5/3A/3B/3C Rab3 CSP Bassoon Piccolo Rab AXIN RIM Early endosome APC APC β Cat GSK3 β MINT Velis Synapto MUNC13MUN Clathrin 2+ brevin brevin Ca2+ Ca CASK napto Sy SyntaxinSySSyntaxin SyntaxinSSyntaxin ACh R MUNC18 SNAP25 SNAP25 Ca2+ Neurotransmitters LAR CN R SynCam nCadherin NetrinG EphrinA EphrinB Neurexin Ca2+ channel Ca2+ channelnnel NGL CN R EphA EphB NMDA R AMPAA R Kainate R mGluR SynCam LRRTM nCadherin Ca2+2+ Neuroligin Ub CaM CaM AKAP79/150 Src MaGUK Ub Tiam Ubb AKAP79/150 PSD95 Kalirin7 Syndecan Calcineurin Src PKAA Calcineurin ArcArc UbU Spectrin Src PKAA Calcineurin PSD95 PSD95 Syntenin Ub Src SynGap PP1 2+ Ca Homer GKAP/ Ephexin1 Vav2 SAPAP Homer p190RhoGAP BetaPIX CaMKI CaMKK NFAT RASGRF ProSAP/Shank Cortacin GTPP GDPDP Rho Rho Kalirin7 CaMKII Ras Ras RAF Actin GDPG GTPG GTPP MEK Rac Rac NFκB GDPG ERK Axonal Actin Spinogenesis Synapse development, Neuronal Receptor Synaptic guidance reorganization function, and plasticity survival trafficking signaling Discover more at abcam.com/biochemicals Produced in collaboration with Paul L. Greer, Ph.D., Harvard Medical School Copyright © 2012 Abcam, All Rights Reserved. Excitatory synapse related products from Abcam Biochemicals Product Biological description Purity Product code Product Biological description Purity Product code Muscarinic Glutamate: mGlu (continued) Acetylcholine Chloride Endogenous neurotransmitter active at acetylcholine receptors - ab120469 mGlu Antagonists Kit A collection of 6 antagonists for mGlu receptor subtypes - ab120322 4-DAMP Muscarinic receptor antagonist >98% ab120144 MMPIP mGlu7 allosteric antagonist >98% ab120245 Pirenzepine dihydrochloride Selective M1 receptor antagonist >99% ab120153 MPEP hydrochloride Potent, selective mGlu5 antagonist >99% ab120008 YM 202074 mGlu1 antagonist >98% ab120293 Nicotinic (±)-Anatoxin A fumarate Potent nicotinic agonist >98% ab120013 Glutamate: NMDA α-Bungarotoxin Subtype-selective α7 nAChR antagonist >99% ab120542 D-AP5 NMDA glutamate site antagonist >99% ab120003 Methyllycaconitine citrate α7-nicotinic receptor antagonist >98% ab120072 7-Chlorokynurenic acid sodium salt NMDA receptor glycine site antagonist; water soluble >99% ab120255 PNU 282987 Selective α7 nAChR agonist >99% ab120558 (R)-CPPene Potent competitive NMDA antagonist >98% ab120232 (+)-Tubocurarine ACh receptor antagonist >99% ab120073 5,7-Dichlorokynurenic acid sodium salt NMDA receptor glycine site antagonist; water soluble >99% ab120254 Vecuronium bromide Competitive nicotinic acetylcholine receptor (nAChR) antagonist - ab120536 (+)-MK 801 maleate Non-competitive NMDA antagonist >99% ab120027 NMDA Excitotoxic amino acid >98% ab120052 Glutamate: broad spectrum/non-selective UBP141 GluN2D (formerly NR2D) antagonist, with some subunit selectivity >98% ab120193 DL-AP4 Broad spectrum glutamate antagonist >99% ab120001 L-Glutamate Excitatory neurotransmitter >99% ab120049 Glutamate: AMPA&Kainate Ibotenic acid Excitotoxic agonist >98% ab120041 (S)-AMPA AMPA agonist >98% ab120005 Kynurenic acid sodium salt Endogenous ionotropic / nicotinic antagonist; water soluble >99% ab120256 CNQX disodium salt AMPA / kainate antagonist (water soluble) >99% ab120044 GYKI 53655 hydrochloride Non-competitive AMPA / kainate receptor antagonist >99% ab120490 Glutamate: mGlu Ionotropic Agonists Kit A collection of 8 agonists, antagonists and potentiators at AMPA, AMN082 dihydrochloride mGlu7 agonist >99% ab120011 Kainate and NMDA receptors. - ab120323 L-AP4 Selective group III mGlu agonist >99% ab120002 Kainic acid Prototypic kainate receptor agonist >99% ab120100 (R,S)-CHPG Selective mGlu5 agonist >98% ab120039 NBQX disodium salt AMPA / kainate antagonist (water soluble) >98% ab120046 Cinnabarinic acid Endogenous mGlu4 selective agonist >98% ab120506 (S)-3,5-DHPG Selective group I mGlu agonist >99% ab120007 Calcium channel LY 341495 Potent, selective group II antagonist. Group III antagonist at higher concentrations >98% ab120199 ω-Agatoxin IVA Ca2+ channel blocker (P and Q type) >95% ab120210 2+ LY 367385 mGlu1a antagonist >99% ab120067 ω-Conotoxin GVIA Ca channel blocker (N type) >96% ab120215 2+ (S)-MCPG Group I / II mGlu antagonist >98% ab120059 SNX 482 R-Type Ca (Cav2.3) channel blocker >96% ab120259 mGlu Agonists Kit A collection of 7 agonists and modulators for a range of mGlu receptor subtypes - ab120321 Verapamil hydrochloride L-type Ca2+ channel blocker >99% ab120140 Featured products Pitstop 2™ clathrin inhibitor - RuBi-Glutamate: A novel light-sensitive, Fluorescent false neurotransmitter - highly World exclusive! (ab120687) caged ligand (ab120408) efficient optical tracer of dopamine (ab120331) Novel, selective, cell membrane permeable clathrin • Activated by visible wavelengths of light Fluorecsent false neurotransmitter (FFN) acts as a inhibitor. Competitively inhibits clathrin terminal • No need for harmful UV light or expensive quartz optics substrate for the synaptic vesicle monoamine transporter. domain to selectively inhibit clathrin mediated • Fast uncaging speeds - single photochemical step endocytosis (IC50 = 12 μM for inhibition of • Resolution seen at individual synaptic level amphiphysin association of clathrin terminal domain). Releases glutamate after one- or two- photon excitation. • Concentration required does not interfere with Interferes with receptor mediated endocytosis, entry Can be used at low concentrations. Enables normal synaptic function of HIV and synaptic vesicle recycling. photoactivation of neuronal dendrites and circuits. • Compatible with GFP-based tags and other Other caged compounds include RuBi-GABA (ab120409), optical probes RuBi-nicotine (ab120450) and RuBi-AP (ab120410) 121_12_KB Discover more at abcam.com/biochemicals.
Load more

Recommended publications
  • Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission
    The Journal of Neuroscience, September 15, 1998, 18(18):7075–7083 Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission Kristofer A. Radcliffe and John A. Dani Division of Neuroscience, Baylor College of Medicine, Houston, Texas 77030-3498 Synaptic modulation and long-term synaptic changes are initiate calcium-dependent mechanisms that are known to in- thought to be the cellular correlates for learning and memory duce glutamatergic synaptic plasticity. The results with evoked (Madison et al., 1991; Aiba et al., 1994; Goda and Stevens, synaptic currents showed that nAChR activity can alter the 1996). The hippocampus is a center for learning and memory relationship between the incoming presynaptic activity and that receives abundant cholinergic innervation and has a high outgoing postsynaptic signaling along glutamatergic fibers. density of nicotinic acetylcholine receptors (nAChRs) (Wada et Thus, the same information arriving along the same glutama- al., 1989; Woolf, 1991). We report that strong, brief stimulation tergic afferents will be processed differently when properly of nAChRs enhanced hippocampal glutamatergic synaptic timed nicotinic activity converges onto the glutamatergic pre- transmission on two independent time scales and altered the synaptic terminals. Influencing information processing at gluta- relationship between consecutively evoked synaptic currents. matergic synapses may be one way in which nicotinic cholin- The nicotinic synaptic enhancement required extracellular cal- ergic activity influences cognitive processes. Disruption of cium and was produced by the activation of presynaptic a7- these nicotinic cholinergic mechanisms may contribute to the containing nAChRs. Although one form of glutamatergic en- deficits associated with the degeneration of cholinergic func- hancement lasted only for seconds, another form lasted for tions during Alzheimer’s disease.
    [Show full text]
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
    [Show full text]
  • Neuronal Nicotinic Receptors: from Structure to Pathology
    Progress in Neurobiology 74 (2004) 363–396 www.elsevier.com/locate/pneurobio Neuronal nicotinic receptors: from structure to pathology C. Gotti, F. Clementi* CNR, Institute of Neuroscience, Cellular and Molecular Pharmacology Section, Department of Medical Pharmacology and Center of Excellence on Neurodegenerative Diseases, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy Received 22 July 2004; accepted 29 September 2004 Available online 27 October 2004 Abstract Neuronal nicotinic receptors (NAChRs) form a heterogeneous family of ion channels that are differently expressed in many regions of the central nervous system (CNS) and peripheral nervous system. These different receptor subtypes, which have characteristic pharmacological and biophysical properties, have a pentameric structure consisting of the homomeric or heteromeric combination of 12 different subunits (a2–a10, b2–b4). By responding to the endogenous neurotransmitter acetylcholine, NAChRs contribute to a wide range of brain activities and influence a number of physiological functions. Furthermore, it is becoming evident that the perturbation of cholinergic nicotinic neurotransmission can lead to various diseases involving nAChR dysfunction during development, adulthood and ageing. In recent years, it has been discovered that NAChRs are present in a number of non-neuronal cells where they play a significant functional role and are the pathogenetic targets in several diseases. NAChRs are also the target of natural ligands and toxins including nicotine (Nic), the most widespread drug of abuse. This review will attempt to survey the major achievements reached in the study of the structure and function of NAChRs by examining their regional and cellular localisation and the molecular basis of their functional diversity mainly in pharmacological and biochemical terms.
    [Show full text]
  • Prefrontal Α7nachr Signaling Differentially Modulates Afferent
    Research Articles: Systems/Circuits Prefrontal α7nAChR signaling differentially modulates afferent drive and trace fear conditioning behavior in adolescent and adult rats https://doi.org/10.1523/JNEUROSCI.1941-20.2020 Cite as: J. Neurosci 2021; 10.1523/JNEUROSCI.1941-20.2020 Received: 27 July 2020 Revised: 29 November 2020 Accepted: 23 December 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 the authors 1 Prefrontal α7nAChR signaling differentially modulates afferent drive 2 and trace fear conditioning behavior in adolescent and adult rats 3 4 5 6 7 Running title: Prefrontal α7nAChR control of afferent drive 8 9 10 11 Anabel M. M. Miguelez Fernandez, Hanna M. Molla, Daniel R. Thomases, and Kuei Y. Tseng* 12 13 Department of Anatomy and Cell Biology, University of Illinois at Chicago, IL 14 15 16 17 *Corresponding Author: Kuei Y. Tseng, MD, PhD 18 Department of Anatomy and Cell Biology 19 University of Illinois at Chicago – College of Medicine 20 Chicago, IL 60612, USA 21 Email: [email protected] 22 23 24 Number of figures: 8 25 Number of tables: 0 26 Abstract: 250 27 Main text: 4,030 words (Introduction: 451; Methods: 1,205; Results: 979; Discussion: 1,395) 28 29 30 31 32 Acknowledgements 33 Supported by NIH Grants R01-MH086507 and R01-MH105488 to KYT, and UIC College of Medicine 34 funds to KYT.
    [Show full text]
  • Whittle-Neuropharm-2013.Pdf
    Neuropharmacology 64 (2013) 414e423 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model Nigel Whittle a,*, Claudia Schmuckermair a, Ozge Gunduz Cinar b,d, Markus Hauschild a, Francesco Ferraguti c, Andrew Holmes b,d, Nicolas Singewald a a Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 80 e 82/III, A-6020 Innsbruck, Austria b Laboratory of Behavioral and Genomic Neuroscience, National Institute on Alcoholism and Alcohol Abuse, National Institutes of Health, Bethesda, MD 20852, USA Center for Neuroscience and Regenerative Medicine at the Uniformed Services University of the Health Sciences, Bethesda, MD c Department of Pharmacology, Innsbruck Medical University, A-6020 Innsbruck, Austria d Center for Neuroscience and Regenerative Medicine at the Uniformed Services University of the Health Sciences, Bethesda, MD, USA article info abstract Article history: Anxiety disorders are characterized by persistent, excessive fear. Therapeutic interventions that reverse Received 30 March 2012 deficits in fear extinction represent a tractable approach to treating these disorders. We previously re- Received in revised form ported that 129S1/SvImJ (S1) mice show no extinction learning following normal fear conditioning. We 31 May 2012 now demonstrate that weak fear conditioning does permit fear reduction during massed extinction Accepted 6 June 2012 training in S1 mice, but reveals specificdeficiency in extinction memory consolidation/retrieval. Rescue of this impaired extinction consolidation/retrieval was achieved with D-cycloserine (N-methly-D-aspar- Keywords: tate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training.
    [Show full text]
  • Alkaloids Pp. 178-End.Pdf
    Hydrastine Found in the roots and rhizomes of Hydrastis canadensis (family: Ranunculaceae). Uses: To control uterine hemorrhage. Traditional use of this root as: 1. Tonic {a medicine that strengthens). Abusamra Yousef Dr. 2. Uterine hemorrhage. 3. Catarrhal conditions. 178 Berberine: Berberies species) and)البرباريسية From Berberidaceae . .(Hydrastis)الفصيلة ال َح ْوذانية Ranunculaceae . Used as antiemetic, antibacterial and anti-inflammatory. Also, it is used for liver diseases. Sanguinarine: blood) دموية From the roots of Sanguinaria canadensis . Dr. Yousef Abusamra Yousef Dr. root) {Family Papaveraceae}. Native to America. Its effect resembles colchicine, i.e. causes doubling of chromosomes number (polyploidy). 179 . Used for atonic dyspepsia with hepatic symptoms. عسر الهضم Jatrorrhizine A protoberberine Benefits: alkaloid Antifungal, antibacterial, Antidiabetic, antiinflammatory. Dr. Yousef Abusamra Yousef Dr. Berberine 180 A quaternary amine alkaloid. Hydrastine Curare alkaloids: Bis-benzylisoquinoline. obtained from the bark and stems of Chondrodendrum tomentosum (family: Menispermaceae). The name is derived from “urari”; an Indian word indicating “poison”. The term “curare” is used to indicate the crude extract prepared from different species. Abusamra Yousef Dr. Was used by certain natives of the Amazon regions of South America as arrow poison. Some of these extracts were poisonous by virtue of a convulsant action and 181 others by paralyzing action (Most remarkable). Mechanism of action of d-tubocurarine Dr. Yousef Abusamra Yousef Dr. 182 • Curare possesses: 1. A paralyzing effect on voluntary muscles. 2. A toxic effect on blood vessels. 3. A histamine–like effect. Most of the activity is attributed to d-tubocurarine. Uses: 1- In surgical anesthesia, as it produces muscular relaxation without deep anesthesia.
    [Show full text]
  • Differing Time Dependencies of Object Recognition Memory Impairments Produced by Nicotinic and Muscarinic Cholinergic Antagonism in Perirhinal Cortex
    Downloaded from learnmem.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Research Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex Chris J. Tinsley,1,3 Nadine S. Fontaine-Palmer,1 Maria Vincent,1 Emma P.E. Endean,1 John P. Aggleton,2 Malcolm W. Brown,1 and E. Clea Warburton1 1MRC Centre for Synaptic Plasticity, School of Physiological Sciences, Bristol University, Bristol BS8 1TD, United Kingdom; 2School of Psychology, Cardiff University, Cardiff CF10 3AT, United Kingdom The roles of muscarinic and nicotinic cholinergic receptors in perirhinal cortex in object recognition memory were com- pared. Rats’ discrimination of a novel object preference test (NOP) test was measured after either systemic or local infusion into the perirhinal cortex of the nicotinic receptor antagonist methyllycaconitine (MLA), which targets alpha-7 (a7) amongst other nicotinic receptors or the muscarinic receptor antagonists scopolamine, AFDX-384, and pirenzepine. Methyllycaconitine administered systemically or intraperirhinally before acquisition impaired recognition memory tested after a 24-h, but not a 20-min delay. In contrast, all three muscarinic antagonists produced a similar, unusual pattern of impairment with amnesia after a 20-min delay, but remembrance after a 24-h delay. Thus, the amnesic effects of nicotinic and muscarinic antagonism were doubly dissociated across the 20-min and 24-h delays. The same pattern of shorter-term but not longer-term memory impairment was found for scopolamine whether the object preference test was carried out in a square arena or a Y-maze and whether rats of the Dark Agouti or Lister-hooded strains were used.
    [Show full text]
  • Neuronal Nicotinic Receptors
    NEURONAL NICOTINIC RECEPTORS Dr Christopher G V Sharples and preparations lend themselves to physiological and pharmacological investigations, and there followed a Professor Susan Wonnacott period of intense study of the properties of nAChR- mediating transmission at these sites. nAChRs at the Department of Biology and Biochemistry, muscle endplate and in sympathetic ganglia could be University of Bath, Bath BA2 7AY, UK distinguished by their respective preferences for C10 and C6 polymethylene bistrimethylammonium Susan Wonnacott is Professor of compounds, notably decamethonium and Neuroscience and Christopher Sharples is a hexamethonium,5 providing the first hint of diversity post-doctoral research officer within the among nAChRs. Department of Biology and Biochemistry at Biochemical approaches to elucidate the structure the University of Bath. Their research and function of the nAChR protein in the 1970’s were focuses on understanding the molecular and facilitated by the abundance of nicotinic synapses cellular events underlying the effects of akin to the muscle endplate, in electric organs of the acute and chronic nicotinic receptor electric ray,Torpedo , and eel, Electrophorus . High stimulation. This is with the goal of affinity snakea -toxins, principallyaa -bungarotoxin ( - Bgt), enabled the nAChR protein to be purified, and elucidating the structure, function and subsequently resolved into 4 different subunits regulation of neuronal nicotinic receptors. designateda ,bg , and d .6 An additional subunit, e , was subsequently identified in adult muscle. In the early 1980’s, these subunits were cloned and sequenced, The nicotinic acetylcholine receptor (nAChR) arguably and the era of the molecular analysis of the nAChR has the longest history of experimental study of any commenced.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Nociceptive Thresholds Are Controlled Through Spinal ОІ2-Subunit
    PAINÒ 152 (2011) 2131–2137 www.elsevier.com/locate/pain Nociceptive thresholds are controlled through spinal b2-subunit-containing nicotinic acetylcholine receptors Ipek Yalcin a, Alexandre Charlet a,b, Matilde Cordero-Erausquin a, Luc-Henri Tessier a, Marina R. Picciotto c, ⇑ Rémy Schlichter a,b, Pierrick Poisbeau a,b, Marie-José Freund-Mercier a,b, Michel Barrot a, a Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France b Faculté des Sciences de la Vie, Université de Strasbourg, Strasbourg, France c Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. article info abstract Article history: Although cholinergic drugs are known to modulate nociception, the role of endogenous acetylcholine in Received 13 October 2010 nociceptive processing remains unclear. In the current study, we evaluated the role of cholinergic trans- Received in revised form 8 April 2011 mission through spinal b2-subunit-containing nicotinic acetylcholine receptors in the control of nocicep- Accepted 8 May 2011 tive thresholds. We show that mechanical and thermal nociceptive thresholds are significantly lowered ⁄ ⁄ in b2 -knockout (KO) mice. Using nicotinic antagonists in these mice, we demonstrate that b2 -nAChRs are responsible for tonic inhibitory control of mechanical thresholds at the spinal level. We further Keywords: hypothesized that tonic b ⁄-nAChR control of mechanical nociceptive thresholds might implicate GAB- Nicotinic 2 Aergic transmission since spinal nAChR stimulation can enhance inhibitory transmission. Indeed, the b -nAChRs 2 ⁄ Acetylcholine GABAA receptor antagonist bicuculline decreased the mechanical threshold in wild-type but not b2 -KO ⁄ ⁄ GABA mice, and the agonist muscimol restored basal mechanical threshold in b2 -KO mice.
    [Show full text]
  • Activation of Group I Metabotropic Glutamate Receptors Potentiates Heteromeric Kainate Receptors
    1521-0111/83/1/106–121$25.00 http://dx.doi.org/10.1124/mol.112.081802 MOLECULAR PHARMACOLOGY Mol Pharmacol 83:106–121, January 2013 Copyright ª 2013 by The American Society for Pharmacology and Experimental Therapeutics Activation of Group I Metabotropic Glutamate Receptors Potentiates Heteromeric Kainate Receptors Asheebo Rojas, Jonathon Wetherington, Renee Shaw, Geidy Serrano, Sharon Swanger, and Raymond Dingledine Department of Pharmacology, Emory University, Atlanta, Georgia Received August 10, 2012; accepted October 11, 2012 ABSTRACT Kainate receptors (KARs), a family of ionotropic glutamate KARs by mGlu1 activation was attenuated by GDPbS, blocked receptors, are widely expressed in the central nervous system by an inhibitor of phospholipase C or the calcium chelator 1,2- and are critically involved in synaptic transmission. KAR bis(o-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid (BAPTA), activation is influenced by metabotropic glutamate receptor prolonged by the phosphatase inhibitor okadaic acid, but un- (mGlu) signaling, but the underlying mechanisms are not affected by the tyrosine kinase inhibitor lavendustin A. Protein understood. We undertook studies to examine how mGlu kinase C (PKC) inhibition reduced the potentiation by mGlu1 of modulation affects activation of KARs. Confocal immunohisto- GluK2/GluK5, and conversely, direct activation of PKC by chemistry of rat hippocampus and cultured rat cortex revealed phorbol 12-myristate,13-acetate potentiated GluK2/GluK5. Using colocalization of the high-affinity KAR subunits with group I site-directed mutagenesis, we identified three serines (Ser833, mGlu receptors. In hippocampal and cortical cultures, the Ser836, and Ser840) within the membrane proximal region of the calcium signal caused by activation of native KARs was po- GluK5 C-terminal domain that, in combination, are required for tentiated by activation of group I mGlu receptors.
    [Show full text]